Amarin Faces Another Generic Threat With Dr. Reddy’s Approval

Amarin briefly fell as much as 2.3% after the FDA approved Dr. Reddy’s icosapent ethyl, a generic form of the heart drug Vascepa.

• The FDA decision, dated Aug. 7, follows a court decision in March where Vascepa’s patents were invalidated; Amarin pledged to appeal
• NOTE: Hikma received approval for its generic Vascepa in May

To contact the reporter on this story:
Catherine Larkin in Chicago at clarkin4@bloomberg.net

To contact the editors responsible for this story:
Courtney Dentch at cdentch1@bloomberg.net

Lisa Wolfson

© 2020 Bloomberg L.P. All rights reserved. Used with permission.